Compare FBIZ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | MYGN |
|---|---|---|
| Founded | 1909 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.9M | 444.2M |
| IPO Year | 2012 | 1996 |
| Metric | FBIZ | MYGN |
|---|---|---|
| Price | $55.74 | $4.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $65.00 | $7.64 |
| AVG Volume (30 Days) | 40.3K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $15.69 | $6.86 |
| Revenue Next Year | $8.47 | $5.45 |
| P/E Ratio | $9.67 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $45.90 | $3.76 |
| 52 Week High | $60.54 | $8.59 |
| Indicator | FBIZ | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 48.86 |
| Support Level | $53.56 | $4.25 |
| Resistance Level | $59.76 | $5.52 |
| Average True Range (ATR) | 1.36 | 0.30 |
| MACD | -0.20 | 0.02 |
| Stochastic Oscillator | 20.26 | 45.24 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.